Company: BIAF
Filing Date: 2025-08-14
Form Type: 10-Q
Source: 0001641172-25-024163
Chunk: 30

Company: bioAffinity Technologies, Inc.
Filing Date: 2025-08-14
Form: 10-Q
Item: Part I, Item 8
Chunk 30
---
 the Warrant Stockholder Approval (the “Stockholder
Approval Notice Date”) and the effective date of the filing of the Certificate of Amendment..

The
Company agreed not to consummate a subsequent offering of its securities at a price less than the exercise price of the May 2025 Warrants
immediately prior to such subsequent offering (a “Dilutive Issuance”) until the earlier of (i) eight months from the closing
date of the Offering; and (ii) later of: (a) the filing of a registration statement registering certain shares of Common Stock issuable
as a result of the Anti-Dilution Adjustment; (b) the Stockholder Approval Notice Date; and (c) the effective date of the filing of the
Certificate of Amendment. Based on an initial exercise price of $0.352 per share (equal to 110% of the combined offering price per Share
and accompanying May 2025 Warrant), if a reverse stock split is effected an additional 4,570,312 shares of Common Stock (on a pre-reverse
stock split basis which number shall be adjusted based on the reverse stock split ratio) will be issuable upon exercise of the May 2025
Warrants and then, subject to obtaining Warrant Stockholder Approval, if a Dilutive Issuance is consummated, an additional 49,907,811
shares of Common Stock (on a pre-reverse stock split basis which number shall be adjusted based on the reverse stock split ratio) would
be issuable upon exercise of the May 2025 Warrants.

The
exercise price of the May 2025 Warrants and number of shares of Common Stock issuable upon exercise thereof will also adjust in the event
of certain stock dividends and distributions, stock splits, stock combinations, reclassifications or similar events.

The
pre-funded warrants may be exercised on a cashless basis at any time at an exercise price of $0.007 per share. The May 2025 Warrants
may be exercised on a cashless basis if at the time of exercise there is no effective registration statement registering, or the prospectus
contained therein is not available for, the issuance of the May 2025 Warrant Shares to the holder, provided however that those purchasers
who do not enter into the Purchase Agreement and do not provide the Company with information required for registration of the resale
of shares of Common Stock shall not have any of their shares issuable as a result of an Anti-D